ClinicalTrials.gg
TerminatedNCT05353439Updated Nov 10, 2026Results posted

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

A Phase 1 interventional study of Biopsy Procedure and Biospecimen Collection in Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma and Platinum-Resistant Lung Small Cell Carcinoma, sponsored by National Cancer Institute (NCI). Terminated at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

How we know · 10 judgments · 2 readings being read again

Why this study was terminated
Withdrawal of tazemetostat supply led to early study closure.
Updated Nov 10, 2026Now TerminatedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 65 studies in Small Cell Lung Carcinoma by National Cancer Institute (NCI) — 5 open to participants now, 15 under way, none of them phase 3. Small Cell Lung Carcinoma · National Cancer Institute (NCI).

Enrollment
40th of 55
22 · median 40
Started
2022
the only one that year
Phase 1
20 of 65
2 open now
Registered
60th of 65
by date

Among the 65 studies in Small Cell Lung Carcinoma by National Cancer Institute (NCI), this one is the 40th largest by enrollment of the 55 interventional ones that give a count, is the only one that started in 2022, is one of 20 in phase 1, and was the 60th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

5 of the 65 studies in Small Cell Lung Carcinoma by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Small Cell Lung Carcinoma by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of tazemetostat hydrobromide (tazemetostat) in combination with topotecan hydrochloride (topotecan) and pembrolizumab in patients with recurrent extensive stage (ES)-small cell lung cancer (SCLC), by reviewing dose-limiting toxicities (DLTs) in cycle 1 (21 days). (Dose-Escalation Cohort) II. To select the recommended phase II dose (RP2D) for a combination of tazemetostat, topotecan and pembrolizumab, based on pharmacodynamic (PD) parameters as well as overall efficacy and tolerability. (Dose-Escalation Cohort) III. To evaluate safety and tolerability of tazemetostat in combination with topotecan and pembrolizumab. (Expansion Cohort)

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. II. To determine in a very preliminary fashion, the efficacy of a combination of tazemetostat, topotecan and pembrolizumab in recurrent ES-SCLC by assessing overall response rate (ORR), progression-free survival (PFS), duration of response (DOR) and overall survival (OS).

EXPLORATORY OBJECTIVES:

I. To perform molecular profiling assays on malignant and normal tissues, including, but not limited to ribonucleic acid (RNA) sequencing (RNA-Seq).

II. To assess modulation of EZH2 targets including SLFN11 and MHC among others. III. To identify potential predictive biomarkers of response. IV. To identify mechanisms of drug sensitivity and resistance using deoxyribonucleic acid (DNA)- and RNA-based assessment platforms.

V. To contribute genetic analysis data from de-identified biospecimens to Genomic Data Commons (GDC), a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data, including presentation, diagnosis, staging, summary treatment, and if possible, outcome.

VI. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) at Nationwide Children's Hospital.

VII. To characterize circulating cell-free DNA (cfDNA).

OUTLINE: This is a dose-escalation study of tazemetostat followed by a dose-expansion study.

Patients receive tazemetostat orally (PO) twice daily (BID) for 7 days prior to cycle 1 and then on days 1-21 of each cycle, pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle, and topotecan IV over 30 minutes on days 1-3 or days 1-5 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan throughout the study and undergo biopsy and collection of blood on study.

After completion of study treatment, patients are followed every 3 months after removal from study treatment until study closure or death, whichever occurs first.

03

Conditions studied

  • Extensive Stage Lung Small Cell Carcinoma
  • Limited Stage Lung Small Cell Carcinoma
  • Platinum-Resistant Lung Small Cell Carcinoma
  • Platinum-Sensitive Lung Small Cell Carcinoma
  • Recurrent Extensive Stage Lung Small Cell Carcinoma
  • Recurrent Lung Small Cell Carcinoma

Keywords

  • SCLC
  • EZH2
  • Tazemetostat
  • Epigenetic priming
  • Topotecan
  • Pembrolizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients enrolled to the primary cohort must have limited- or extensive-disease SCLC at diagnosis, with relapse at study entry with per (RECIST) 1.1, and with prior therapy with platinum doublet. Patients with extensive stage disease should have received chemo-immunotherapy. Both platinum-sensitive and platinum-resistant patients will be included
  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of pembrolizumab in combination with tazemetostat and topotecan in patients \< 18 years of age, children are excluded from this study
  • (ECOG) performance status =\< 2 ( >= 70%)
  • Leukocytes >= 3000/mcL
  • >= 1,500/mcL
  • >= 100,000/mcL
  • >= 9 g/dL or >= 5.6 mmol/L
  • Total =\< 1.5 institutional (ULN) OR direct bilirubin =\< ULN for patients with total bilirubin levels > 1.5 × ULN
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 2.5 x institutional ULN
  • Creatinine =\< 1.5 institutional ULN OR (GFR) >= 60 mL/min/1.73 m\^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m\^2

    • Note: (CrCl) should be calculated per institutional standard. Glomerular filtration rate (GFR) can also be used in place of creatinine or CrCl
  • (INR) or prothrombin time (PT) =\< 1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
  • Activated (a)PTT =\< 1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load ( of greater than 250 cells/mcL) within 6 months are eligible for this trial. They must not be receiving prophylactic therapy for an opportunistic infection
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with treated are eligible if they are symptomatically stable while off therapy for a minimum of 7 days
  • Patients should be class 2B or better on the Functional Classification
  • Ability to understand and the willingness to sign a written document
  • The effects of pembrolizumab and tazemetostat on the developing human fetus are unknown. For this reason and because monoclonal antibodies, EZH2 inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment and for 6 months after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of study treatment administration

Exclusion criteria

Exclusion Criteria:

  • Patients who have had chemotherapy, , or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.

    • Note: Patients who have had palliative radiotherapy may be included as long as they have recovered from any radiotherapy related adverse events (allow at least 3 days between radiotherapy completion and study treatment)
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1).

    • Note: Patients with =\< grade 2 neuropathy or =\< grade 2 alopecia are an exception to this criterion and may qualify for the study
    • Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Untreated immunodeficiency or receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the study principal investigator (PI)
  • Patients who are receiving any other agents
  • Patients with symptomatic are not eligible due to their extremely poor prognosis and since it is unclear whether the investigational agent penetrates the blood-brain barrier. However, subjects who have had treatment for their brain metastasis and are symptomatically stable while off steroid therapy for a minimum of 7 days may be enrolled. The use of physiologic doses of corticosteroids may be approved after consultation with the study PI
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab and tazemetostat or other agents used in study
  • Has an active disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
  • Patients with uncontrolled intercurrent illness but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because pembrolizumab as a monoclonal antibody, and tazemetostat as a EZH2 inhibitor may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pembrolizumab or tazemetostat, breastfeeding should be discontinued if the mother is treated with these agents and for 1 week after the last dose of tazemetostat. These potential risks may also apply to other agents used in this study
  • Has known active (e.g., hepatitis B surface antigen [HBsAg] reactive) or
  • Has received a within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted
  • Has thrombocytopenia, neutropenia, or anemia of grade >= 3 (per [CTCAE] 5.0 criteria) or any prior history of myeloid , including myelodysplastic syndrome (MDS)
  • Has abnormalities known to be associated with MDS (e.g. del 5q, chromosome [chr] 7 abnormality [abn]) and myeloproliferative neoplasm (MPN) (e.g. JAK2 V617F) observed in cytogenetic testing and DNA sequencing
  • Has a prior history of T-cell lymphoblastic lymphoma (T-LBL), T-cell acute leukemia (T-ALL) or B-cell acute lymphoblastic leukemia (B-ALL)
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Treatment (tazemetostat, pembrolizumab, topotecan)

    Patients receive tazemetostat PO BID for 7 days prior to cycle 1 and then on days 1-21 of each cycle, pembrolizumab IV over 30 minutes on day 1 of each cycle, and topotecan IV over 30 minutes on days 1-3 or days 1-5 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study and undergo biopsy and collection of blood on study.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Biological: Pembrolizumab · Drug: Tazemetostat Hydrobromide · Drug: Topotecan Hydrochloride

Interventions

  • ProcedureBiopsy Procedure

    Undergo biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo collection of blood

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • BiologicalPembrolizumab

    Given IV

    Also known as: BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475

  • DrugTazemetostatBeing read again: the record changed after it was read.Studies of TazemetostatTazemetostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: EPZ-6438 Monohydrobromide, Tazemetostat Monohydrobromide, TAZVERIK

  • DrugTopotecanBeing read again: the record changed after it was read.Studies of TopotecanTopotecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (Dose-escalation Cohort) of Tazemetostat in Combination With Topotecan and Pembrolizumab

    Maximum tolerated dose (MTD) is the highest dose level with observed toxicity rate less than 33%.

    Time frame: Up to 21 days (cycle 1)

  2. Incidence of Adverse Events (Expansion Cohort) by Type and Grade in the Expansion Cohort

    The incidence of adverse events will be reported by type and grade, for the participants in the expansion cohort. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is serious. Grade 4 is life-threatening. Grade 5 is death related to adverse event.

    Time frame: Up to 3 years

  3. Incidence of Grade 3 or Above Adverse Events by Type Related or Possibly Related to Study Treatment in the Dose Escalation Cohort

    Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is serious. Grade 4 is life-threatening. Grade 5 is death related to adverse event.

    Time frame: Start of treatment through 30 days post last dose, an average of 112.33 days or 3.22 months

Secondary outcomes

  1. Overall Response Rate (ORR) (Expansion Cohort)

    ORR will be estimated based on participants evaluable for response and will be presented along with a 95% confidence interval. ORR was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Complete Response (CR) is disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions.

    Time frame: Up to 3 years

  2. Progression-free Survival (PFS) (Expansion Cohort)

    PFS will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. PFS is defined as the duration of time from start of treatment to time of progression or death. PFS was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Progression is defined as at least 1 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.

    Time frame: From the on-study date until the date of progression or death without progression, assessed up to 3 years

  3. Overall Survival (OS) (Expansion Cohort)

    OS will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. OS is determined from the on-study date until the date of death without progression. Progression was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria and is defined as at least a 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.

    Time frame: From the on-study date until the date of death or last follow-up, assessed up to 3 years

  4. Duration of Response (DOR) (Expansion Cohort)

    DOR will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. DOR is calculated from the first date of response to the date of progression. Response was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.

    Time frame: From the first date of response to the date of progression, assessed up to 3 years

  5. Gene Expression Estimated by the Ribonucleic Acid (RNA) Sequencing in Participants With Recurrent Extensive Stage Small Cell Lung Cancer (ES-SCLC) (Dose Expansion)

    RNA Seq molecular profiling will be performed on malignant and normal tissue obtained by biopsy.

    Time frame: Baseline, post Tazemetostat (Day 1 Cycle 1/(1 cycle =21 days), and post 3-drug combination

Other outcomes

  1. Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

    Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v50). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    Time frame: From the first study intervention, Study Day 1 of Cycle 1 through 30 days after the study agent (s) was/were administered, an average of 112.33 days or 3.22 months

  2. Number of Participants With a Dose Limiting Toxicity (DLT)

    A DLT is the occurrence of any of the following toxicities, if determined by the Investigator to be possibly, probably or definitely related to study drug administration: Grade 4 nonhematologic toxicity (not laboratory), Neutropenia grade 4 for \>7 days, Grade 3 nonhematologic toxicity (not laboratory) lasting \>3 days despite optimal supportive care, Any grade 3 or 4 nonhematologic laboratory value if medical intervention is required, the abnormality leads to a hospitalization, or the abnormality persists for \>1 week. Febrile neutropenia Grade 3 or Grade 4, Thrombocytopenia \<25,000/mm\^3 if associated with a bleeding event which does not result in hemodynamic instability but requires an elective platelet transfusion, or a life-threatening bleeding event which results in urgent intervention and admission to an Intensive Care Unit. Prolonged delay (.2 weeks) in starting Cycle 2 due to treatment-related toxicity. Grade 5 toxicity.

    Time frame: Cycle 1 (21 days)

07

Results

Posted Nov 10, 2026

Participant flow

Dose Escalation Arm 1 (7-day Induction)
Participant flow — Dose Escalation Arm 1 (7-day Induction)
MilestoneDose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1
Started4116154
7-day induction tazemetostat twice a day (bid) (7 days(d) prior to cycle(c) 1 day 1)0116154
Completed0116154
Not completed4000000
Withdrew: Screen failures4000000
Dose Expansion From Cycle 1 Day 1 Onward
Participant flow — Dose Expansion From Cycle 1 Day 1 Onward
MilestoneDose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1
Started0006154
21-day cycles tazemetostat bid (d1 to d21) + topotecan (d1 to d3 or d1 to d5) + pembrolizumab (d1)0006154
Completed0005154
Not completed0001000
Withdrew: Death0001000

Outcome measures

PrimaryMaximum Tolerated Dose (Dose-escalation Cohort) of Tazemetostat in Combination With Topotecan and Pembrolizumab

Maximum tolerated dose (MTD) is the highest dose level with observed toxicity rate less than 33%.

Time frame:
Up to 21 days (cycle 1)
Reported as:
Number · mg/m^2
Maximum Tolerated Dose (Dose-escalation Cohort) of Tazemetostat in Combination With Topotecan and Pembrolizumab
mg/m^2All Participants in the Dose Escalation Cohort
Maximum Tolerated Dose (Dose-escalation Cohort) of Tazemetostat in Combination With Topotecan and PembrolizumabNA
PrimaryIncidence of Adverse Events (Expansion Cohort) by Type and Grade in the Expansion Cohort

The incidence of adverse events will be reported by type and grade, for the participants in the expansion cohort. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is serious. Grade 4 is life-threatening. Grade 5 is death related to adverse event.

Time frame:
Up to 3 years

No measurements were reported for this outcome.

PrimaryIncidence of Grade 3 or Above Adverse Events by Type Related or Possibly Related to Study Treatment in the Dose Escalation Cohort

Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is serious. Grade 4 is life-threatening. Grade 5 is death related to adverse event.

Time frame:
Start of treatment through 30 days post last dose, an average of 112.33 days or 3.22 months
Reported as:
Number · Adverse events
Incidence of Grade 3 or Above Adverse Events by Type Related or Possibly Related to Study Treatment in the Dose Escalation Cohort
Adverse eventsDose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1
Grade 3 Allergic Reaction0000010
Grade 3 Anemia0004206
Grade 3 GI Bleed0000001
Grade 3 Hypotension0000010
Grade 3 Infusion Related Reaction0000010
Grade 3 Lymphocyte Count Decreased0001121
Grade 3 Neutrophil Count Decreased0005102
Grade 3 Paresthesia0000001
Grade 3 Platelet Count Decreased0002201
Grade 3 White Blood Cell Count Decreased0003300
Grade 4 Delirium0000001
Grade 4 Dyspnea0001000
Grade 4 Lymphocyte Count Decreased0001000
Grade 4 Neutrophil Count Decreased0001000
Grade 4 Platelet Count Decreased0002201
Grade 4 White Blood Cell Count Decreased0001000
Any Grade 50000000
SecondaryOverall Response Rate (ORR) (Expansion Cohort)

ORR will be estimated based on participants evaluable for response and will be presented along with a 95% confidence interval. ORR was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Complete Response (CR) is disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions.

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondaryProgression-free Survival (PFS) (Expansion Cohort)

PFS will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. PFS is defined as the duration of time from start of treatment to time of progression or death. PFS was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Progression is defined as at least 1 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.

Time frame:
From the on-study date until the date of progression or death without progression, assessed up to 3 years

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) (Expansion Cohort)

OS will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. OS is determined from the on-study date until the date of death without progression. Progression was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria and is defined as at least a 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.

Time frame:
From the on-study date until the date of death or last follow-up, assessed up to 3 years

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR) (Expansion Cohort)

DOR will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. DOR is calculated from the first date of response to the date of progression. Response was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.

Time frame:
From the first date of response to the date of progression, assessed up to 3 years

No measurements were reported for this outcome.

SecondaryGene Expression Estimated by the Ribonucleic Acid (RNA) Sequencing in Participants With Recurrent Extensive Stage Small Cell Lung Cancer (ES-SCLC) (Dose Expansion)

RNA Seq molecular profiling will be performed on malignant and normal tissue obtained by biopsy.

Time frame:
Baseline, post Tazemetostat (Day 1 Cycle 1/(1 cycle =21 days), and post 3-drug combination

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v50). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:
From the first study intervention, Study Day 1 of Cycle 1 through 30 days after the study agent (s) was/were administered, an average of 112.33 days or 3.22 months
Reported as:
Count of participants · Participants
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
ParticipantsDose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)0116154
Other pre-specifiedNumber of Participants With a Dose Limiting Toxicity (DLT)

A DLT is the occurrence of any of the following toxicities, if determined by the Investigator to be possibly, probably or definitely related to study drug administration: Grade 4 nonhematologic toxicity (not laboratory), Neutropenia grade 4 for \>7 days, Grade 3 nonhematologic toxicity (not laboratory) lasting \>3 days despite optimal supportive care, Any grade 3 or 4 nonhematologic laboratory value if medical intervention is required, the abnormality leads to a hospitalization, or the abnormality persists for \>1 week. Febrile neutropenia Grade 3 or Grade 4, Thrombocytopenia \<25,000/mm\^3 if associated with a bleeding event which does not result in hemodynamic instability but requires an elective platelet transfusion, or a life-threatening bleeding event which results in urgent intervention and admission to an Intensive Care Unit. Prolonged delay (.2 weeks) in starting Cycle 2 due to treatment-related toxicity. Grade 5 toxicity.

Time frame:
Cycle 1 (21 days)
Reported as:
Count of participants · Participants
Number of Participants With a Dose Limiting Toxicity (DLT)
ParticipantsDose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1
Number of Participants With a Dose Limiting Toxicity (DLT)0102101

Adverse events

Collected over All-Cause Mortality was monitored/assessed a median of 5.68 months (range 1.08-37.15 months). Adverse Events were monitored/assessed from the first study intervention, Study Day 1 of Cycle 1 through 30 days after the study agent (s) was/were administered, an average of 3.22 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation, Participants Enrolled But Not Treated0/4 (0%)0/4 (0%)0/4 (0%)
Dose Escalation Arm 1(Induction), Dose Level 11/1 (100%)1/1 (100%)1/1 (100%)
Dose Escalation Arm 1(Induction) Dose Level -20/1 (0%)0/1 (0%)1/1 (100%)
Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 15/6 (83.3%)5/6 (83.3%)6/6 (100%)
Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -11/1 (100%)1/1 (100%)1/1 (100%)
Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -23/5 (60%)2/5 (40%)5/5 (100%)
Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -13/4 (75%)3/4 (75%)4/4 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventDose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1
Alanine aminotransferase increasedInvestigations0/41/10/10/60/11/50/4
Alkaline phosphatase increasedInvestigations0/41/10/10/60/11/50/4
Aspartate aminotransferase increasedInvestigations0/41/10/10/60/11/50/4
Blood bilirubin increasedInvestigations0/41/10/11/60/11/50/4
Death NOSGeneral disorders0/41/10/10/60/10/50/4
Platelet count decreasedInvestigations0/40/10/11/61/10/51/4
AnemiaBlood and lymphatic system disorders0/40/10/11/60/10/52/4
Back painMusculoskeletal and connective tissue disorders0/40/10/10/60/10/51/4
FallInjury, poisoning and procedural complications0/40/10/10/60/10/51/4
Gastric hemorrhageGastrointestinal disorders0/40/10/10/60/10/51/4
Most frequent other events
Showing 10 of 103
Most frequent other events
EventDose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1
Activated partial thromboplastin time prolongedInvestigations0/40/10/10/61/10/51/4
Alanine aminotransferase increasedInvestigations0/41/10/12/60/10/51/4
AnemiaBlood and lymphatic system disorders0/41/10/16/61/11/52/4
AnorexiaMetabolism and nutrition disorders0/41/10/11/60/12/51/4
Aspartate aminotransferase increasedInvestigations0/41/10/12/60/10/52/4
Blood bilirubin increasedInvestigations0/41/10/10/60/11/51/4
Bone painMusculoskeletal and connective tissue disorders0/41/10/10/60/10/50/4
BruisingInjury, poisoning and procedural complications0/40/10/10/61/10/51/4
ChillsGeneral disorders0/40/10/10/61/11/50/4
CholecystitisHepatobiliary disorders0/41/10/10/60/10/50/4

Baseline characteristics

All participants that were enrolled, consented and had data collected are reported in the table.

Age, Categorical
Age, Categorical(Participants)Dose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1Total
<=18 years00000000
Between 18 and 65 years311213112
>=65 years100402310
Age, Continuous
Age, Continuous(years)Dose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1Total
Mean59.5 ± 8.58526267.83 ± 10.746259.8 ± 14.8668.75 ± 8.0263.41 ± 10.61
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1Total
Female301313314
Male11030218
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1Total
Hispanic or Latino10000001
Not Hispanic or Latino311615421
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1Total
American Indian or Alaska Native00000000
Asian10010002
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000000
White311415419
More than one race00000000
Unknown or Not Reported00010001
Region of Enrollment
Region of Enrollment(participants)Dose Escalation, Participants Enrolled But Not TreatedDose Escalation Arm 1(Induction), Dose Level 1Dose Escalation Arm 1(Induction) Dose Level -2Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1Total
United States411615422
08

Study locations

15 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — National Cancer Institute (NCI) is committed to sharing data in accordance with National Institutes of Health (NIH) policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available after publication of the primary study results and completion of regulatory and sponsor review and will remain available in accordance with National Institutes of Health (NIH) data-retention and sharing policies.

Access criteria: De-identified individual participant data and supporting documents may be made available to qualified researchers whose proposed use is consistent with the informed consent, applicable laws and regulations, and National Institutes of Health (NIH)/National Cancer Institute (NCI) data-sharing policies. Requests will be reviewed by NCI, and access may require an approved research proposal and data-use agreement.

Data sharing details ↗ · grants.nih.gov

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2022 to primary completion in Feb 2026, 42 months.

Results were first posted in Nov 2026, 8 months after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Apr 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2022
First posted
Apr 29, 2022
StartActual
Jul 27, 2022
Primary completionActual
Feb 11, 2026
CompletionActual
Apr 21, 2026was Mar 2027
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Withdrawal of tazemetostat supply led to early study closure.
changed Nov 10, 2026
Results
Results posted
posted Nov 10, 2026
Study completion
Mar 13, 2027→Apr 21, 2026 (actual)
Nov 10, 2026
Enrollment
18→22
Nov 10, 2026
Primary outcomes
2 edited, 1 added
What changed in the outcomes
  • EditedMaximum tolerated doseTolerated Dose (doseDose-escalation cohortCohort) of Tazemetostat in Combination With Topotecan and PembrolizumabTime frame: Up to 21 days (cycle 1)
  • EditedIncidence of adverse eventsAdverse Events (expansion cohortExpansion Cohort) by Type and Grade in the Expansion CohortTime frame: Up to 3 years
  • AddedIncidence of Grade 3 or Above Adverse Events by Type Related or Possibly Related to Study Treatment in the Dose Escalation CohortTime frame: Start of treatment through 30 days post last dose, an average of 112.33 days or 3.22 months
Nov 10, 2026
Secondary outcomes
1 edited, 6 added, 3 removed
What changed in the outcomes
  • EditedProgression-free survivalSurvival (PFS) (Expansion Cohort)Time frame: From the on-study date until the date of progression or death without progression, assessed up to 3 years
  • AddedOverall Response Rate (ORR) (Expansion Cohort)Time frame: Up to 3 years
  • AddedOverall Survival (OS) (Expansion Cohort)Time frame: From the on-study date until the date of death or last follow-up, assessed up to 3 years
  • AddedDuration of Response (DOR) (Expansion Cohort)Time frame: From the first date of response to the date of progression, assessed up to 3 years
  • AddedGene Expression Estimated by the Ribonucleic Acid (RNA) Sequencing in Participants With Recurrent Extensive Stage Small Cell Lung Cancer (ES-SCLC) (Dose Expansion)Time frame: Baseline, post Tazemetostat (Day 1 Cycle 1/(1 cycle =21 days), and post 3-drug combination
  • RemovedOverall response rateTime frame: Up to 3 years
  • RemovedOverall survivalTime frame: From the on-study date until the date of death or last follow-up, assessed up to 3 years
  • RemovedDuration of responseTime frame: From the first date of response to the date of progression, assessed up to 3 years
  • Addedother outcomeNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)Time frame: From the first study intervention, Study Day 1 of Cycle 1 through 30 days after the study agent (s) was/were administered, an average of 112.33 days or 3.22 months
  • Addedother outcomeNumber of Participants With a Dose Limiting Toxicity (DLT)Time frame: Cycle 1 (21 days)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Terminated
    Why stopped Withdrawal of tazemetostat supply led to early study closure.
    Results posted
    Study completion Mar 13, 2027→Apr 21, 2026 (now actual)
    Enrollment 18→22
    Primary outcomes 2 edited, 1 added
    What changed in the outcomes
    • EditedMaximum tolerated doseTolerated Dose (doseDose-escalation cohortCohort) of Tazemetostat in Combination With Topotecan and PembrolizumabTime frame: Up to 21 days (cycle 1)
    • EditedIncidence of adverse eventsAdverse Events (expansion cohortExpansion Cohort) by Type and Grade in the Expansion CohortTime frame: Up to 3 years
    • AddedIncidence of Grade 3 or Above Adverse Events by Type Related or Possibly Related to Study Treatment in the Dose Escalation CohortTime frame: Start of treatment through 30 days post last dose, an average of 112.33 days or 3.22 months
    Secondary outcomes 1 edited, 6 added, 3 removed
    What changed in the outcomes
    • EditedProgression-free survivalSurvival (PFS) (Expansion Cohort)Time frame: From the on-study date until the date of progression or death without progression, assessed up to 3 years
    • AddedOverall Response Rate (ORR) (Expansion Cohort)Time frame: Up to 3 years
    • AddedOverall Survival (OS) (Expansion Cohort)Time frame: From the on-study date until the date of death or last follow-up, assessed up to 3 years
    • AddedDuration of Response (DOR) (Expansion Cohort)Time frame: From the first date of response to the date of progression, assessed up to 3 years
    • AddedGene Expression Estimated by the Ribonucleic Acid (RNA) Sequencing in Participants With Recurrent Extensive Stage Small Cell Lung Cancer (ES-SCLC) (Dose Expansion)Time frame: Baseline, post Tazemetostat (Day 1 Cycle 1/(1 cycle =21 days), and post 3-drug combination
    • RemovedOverall response rateTime frame: Up to 3 years
    • RemovedOverall survivalTime frame: From the on-study date until the date of death or last follow-up, assessed up to 3 years
    • RemovedDuration of responseTime frame: From the first date of response to the date of progression, assessed up to 3 years
    • Addedother outcomeNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)Time frame: From the first study intervention, Study Day 1 of Cycle 1 through 30 days after the study agent (s) was/were administered, an average of 112.33 days or 3.22 months
    • Addedother outcomeNumber of Participants With a Dose Limiting Toxicity (DLT)Time frame: Cycle 1 (21 days)
    + 3 other changes: verification date, conditions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05353439
Responsible party
Sponsor
First posted
Apr 29, 2022
Start date
Jul 27, 2022
Primary completion
Feb 11, 2026
Completion
Apr 21, 2026
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

Anish Thomas
principal investigator · National Cancer Institute LAO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tazemetostat

Start the discussion